A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Therapy.

Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2014

At a glance

  • Drugs Dexmecamylamine (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms RENAISSANCE-3
  • Most Recent Events

    • 01 Mar 2014 Results published in the European Neuropsychopharmacology.
    • 28 Mar 2012 Planned patient number is 1024 according to ClinicalTrials.gov.
    • 08 Nov 2011 Primary endpoint 'Montgomery-Asberg-Depression-Rating-Scale' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top